15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inflammation both increases and causes resistance to FGF23 in normal and uremic rats

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibroblast growth factor 23 (FGF23) increases phosphorus excretion and decreases calcitriol (1,25(OH)2D) levels. FGF23 increases from early stages of renal failure. We evaluated whether strict control of phosphorus intake in renal failure prevents the increase in FGF23 and to what extent inflammation impairs regulation of FGF23. The study was performed in 5/6 nephrectomized (Nx) Wistar rats fed diets containing 0.2–1.2% phosphorus for 3 or 15 days. FGF23 levels significantly increased in all Nx groups in the short-term (3-day) experiment. However, at 15 days, FGF23 increased in all Nx rats except in those fed 0.2% phosphorus. In a second experiment, Nx rats fed low phosphorus diets (0.2 and 0.4%) for 15 days received daily intraperitoneal lipopolysaccharide (LPS) injections to induce inflammation. In these rats, FGF23 increased despite the low phosphorus diets. Thus, higher FGF23 levels were needed to maintain phosphaturia and normal serum phosphorus values. Renal Klotho expression was preserved in Nx rats on a 0.2% phosphorus diet, reduced on a 0.4% phosphorus diet, and markedly reduced in Nx rats receiving LPS. In ex vivo experiments, high phosphorus and LPS increased nuclear β-catenin and p65-NFκB and decreased Klotho. Inhibition of inflammation and Wnt signaling activation resulted in decreased FGF23 levels and increased renal Klotho. In conclusion, strict control of phosphorus intake prevented the increase in FGF23 in renal failure, whereas inflammation independently increased FGF23 values. Decreased Klotho may explain the renal resistance to FGF23 in inflammation. These effects are likely mediated by the activation of NFkB and Wnt/β-catenin signaling.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: not found
          • Article: not found

          A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

              Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of disordered phosphorus metabolism in the initial stages of chronic kidney disease (CKD). We measured FGF23 in baseline samples from 3879 patients in the Chronic Renal Insufficiency Cohort study, which is a diverse cohort of patients with CKD stage 2-4. Mean serum phosphate and median parathyroid hormone (PTH) levels were in the normal range, but median FGF23 was markedly greater than in healthy populations, and increased significantly with decreasing estimated glomerular filtration rate (eGFR). High levels of FGF23, defined as being above 100 RU/ml, were more common than secondary hyperparathyroidism and hyperphosphatemia in all strata of eGFR. The threshold of eGFR at which the slope of FGF23 increased was significantly higher than the corresponding threshold for PTH based on non-overlapping 95% confidence intervals. Thus, increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH. Hence, FGF23 measurements may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Clinical Science
                Portland Press Ltd.
                0143-5221
                1470-8736
                January 2020
                January 17 2020
                January 2020
                January 17 2020
                January 03 2020
                : 134
                : 1
                : 15-32
                Affiliations
                [1 ]Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
                [2 ]Universidad de Córdoba, Córdoba, Spain
                [3 ]Hospital Universitario Reina Sofía, Córdoba, Spain
                [4 ]Red Nacional de Investigación en Nefrología (REDinREN), Instituto de Salud Carlos III, Madrid, Spain.
                [5 ]Unidad de Gestión Clínica (UGC) Nefrología, Hospital Universitario Reina Sofía, Córdoba, Spain
                [6 ]Renal, Vascular and Diabetes Research Laboratory, Fundación Instituto de Investigaciones Sanitarias-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
                [7 ]Departamento de Medicina y Cirugía Animal, Universidad de Córdoba, Córdoba, Spain
                [8 ]Nefrología, Instituto de Investigación Sanitaria Fundación Jiménez Díaz-UAM, Madrid, Spain
                [9 ]Unidad de Gestión clínica (UGC) Medicina Interna, Hospital Universitario Reina Sofía, Córdoba, Spain
                [10 ]Centro de Investigación Biomédica en Red Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Córdoba, Spain
                [11 ]Fundación Renal Iñigo Álvarez de Toledo, Madrid, Spain
                [12 ]Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine, University of California, Los Angeles, CA, U.S.A.
                [13 ]European Uremic Toxin (EUTox) Work Group. CKD-MBD Working Group
                Article
                10.1042/CS20190779
                31860056
                f5acf71c-efa3-4d2a-9c24-3628b07677b3
                © 2020
                History

                Comments

                Comment on this article